Experiences with
Chronic leukaemia5,710 public posts
Review article summarises management strategies for those with CLL harbouring complex karyotype
On 6 January 2025, the journal [i]BJ Haem[/i] published a review article titled [i]Management strategies for patients with lymphocytic leukaemia harbouring complex karyotype[/i] written by a team from Padua, Italy.
Additional insights from the 2023 Global Leukemia Experience Survey - CLL specific findings, unmet needs and recommendations for action
As chronic leukaemia progression is slower than acute, the symptom onset can be subtle and take years to have an impact on quality of life. Improving symptom awareness and early health seeking behaviour in the general population and targeted education for primary care clinicians may address this.
Want to take advantage of all our features? Just log in!
or
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Abstract report in New England Journal of Medicine Published February 5, 2025
No real new information here and I'm surprised anyone was recruited for this study as the control arm is chemoimmunotherapy and no account appears to have been taken for unmated IGHV or 17p/TP53 as the patients were
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying CLL patients with early treatment requirement
Most of us would be aware of the prognostic value of the immunoglobulin heavy-chain variable region gene (IGHV) mutation status of our CLL (See https://healthunlocked.com/cllsupport/posts/private/146164102/the-fascinating-history-of-the-importance-of-ighv-mutation-status-in-cll-prognosis-and-treatment
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase. Phase 1 trial results.
Rocbrutinib is a new drug offering hope to patients with what are known as gatekeeper mutations that confer resistance to Pirtobrutinib. This BTKi is unique in being both a covalent and non covalent inhibitor of BTK.
Patients with gatekeeper mutations have poor outcomes and short survival and demonstrate